[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341501-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341501-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mettl3-regulates-thyroid-cancer-differentiation-and-chemosensitivity-by-modulating-pax8","METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8","","Thyroid cancer presents an urgent clinical problem when dedifferentiation drives poor patient outcomes despite generally favorable prognoses. This study investigates how methyltransferase-like 3 (METTL3) mediated N6-methyladenosine (m6A) influences thyroid cancer progression, differentiation, and treatment response. METTL3–PAX8 signaling was assessed through patient biomarker analysis, METTL3 loss-of-function mouse models, RNA sequencing, and in vitro validation. Results show METTL3 suppresses tumor progression, restores chemosensitivity, and interacts with the METTL3/PAX8/YTHDC1 axis antagonized by miR-493-5p.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mettl3-regulates-thyroid-cancer-differentiation-and-chemosensitivity-by-modulating-pax8/341501/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mettl3-regulates-thyroid-cancer-differentiation-and-chemosensitivity-by-modulating-pax8/341501.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main research focus of the study?","Question",{"text":63,"@type":64},"The study examines how METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8, and clarifies the underlying METTL3-associated molecular axis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was METTL3-related correlation with prognosis evaluated?",{"text":68,"@type":64},"METTL3 and prognosis in thyroid cancer patients were assessed using immunohistochemistry.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic sensitivity effects were observed when METTL3 expression changed?",{"text":72,"@type":64},"Silencing METTL3 promoted progression and dedifferentiation, while overexpressing METTL3 enhanced sensitivity of papillary and anaplastic thyroid cancer cells to chemotherapeutic drugs and iodine-131.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341501,1790193883,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Ivyspring  \nInternational Publisher  \nInternationalJournal of Biological Sciences  \n2024; 20(9): 3426-3441. doi: 10.7150/ijbs.84797  \nResearch Paper  \nMETTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8  \nNing Kang1*, Zewei Zhao1*, Zhongyu Wang1*, Junya Ning1, Huijuan Wang1, Wei Zhang1, Xianhui Ruan1􀀍, Ming Gao1,2􀀍, Xiangqian Zheng1􀀍  \n1. Department of Thyroid and Neck Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China.  \n2. Department of Breast and Thyroid Surgery, Tianjin Union Medical Center, No. 190 Jieyuan Road, Hongqiao District, Tianjin 300121, China.  \n*These authors contributed equally to this work.  \n􀀍 Corresponding authors: Correspondence to Zheng Xiangqian ([xzheng05@tmu.edu.cn](xzheng05@tmu.edu.cn)), Gao Ming ([headandneck2007@aliyun.com](headandneck2007@aliyun.com)), Ruan Xianhui ([tjruanxianhui@163.com](tjruanxianhui@163.com)).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.03.30; Accepted: 2024.06.06; Published: 2024.06.17  \nAbstract  \nBackground: Thyroid cancer (TC) is a common endocrine cancer with a favourable prognosis. However, poor patient prognosis due to TC dedifferentiation is becoming an urgent challenge. Recently, methyltransferase-like 3 (METTL3)-mediated N6-methyladenosine (m6A) modification has been demonstrated to play an important role in the occurrence and progression of various cancers and a tumour suppressor role in TC. However, the mechanism of METTL3 in TC remains unclear.  \nMethods: The correlation between METTL3 and prognosis in TC patients was evaluated by immunohistochemistry. Mettl3fl/flBrafV600ETPO-cre TC mouse models and RNA-seq were used to investigate the underlying molecular mechanism, which was further validated by in vitro experiments. The target gene of METTL3 was identified, and the complete m6A modification process was described. The phenomenon of low expression of METTL3 in TC was explained by identifying miRNAs that regulate METTL3.  \nResults: We observed that METTL3 expression was negatively associated with tumour progression and poor prognosis in TC. Mechanistically, silencing METTL3 promoted the progression and dedifferentiation of papillary thyroid carcinoma (PTC) both in vivo and in vitro. Moreover, overexpressing METTL3 promoted the sensitivity of PTC and anaplastic thyroid cancer (ATC) cells to chemotherapeutic drugs and iodine-131 (131I) administration. Overall, the METTL3/PAX8/YTHDC1 axis has been revealed to playa pivotal role in repressing tumour occurrence, and is antagonized by miR-493-5p.  \nKeywords: Thyroid cancer dedifferentiation, chemotherapeutic resistance, N6-methyladenosine (m6A) modification, METTL3, PAX8 .  \nIntroduction  \nThe incidence rate of TC continues to increase worldwide, and it is projected that more than 3.7 million new cases will be diagnosed in the 2028–2032 period in mainland China[1] . Research on TCpathogenesis and improvement of its treatment has had a high profile in recent years. Differentiated TC (DTC) is the most common pathological type of thyroid tumour and has a favourable prognosis with standard treatments, such as surgery, administration of radioactive iodine (RAI) and thyroid-stimulating  \nhormone (TSH) suppressive therapy. However, among DTC patients, approximately 7% develop metastatic disease. Fifty to seventy percent of these patients exhibit loss of iodine-131 (131I) uptake initially or gradually, also known as RAI-refractory DTC (RAIR-DTC) and their 10-year survival rate is then reduced to less than 20%[2] . Among these patients, dedi","cbCaiaekWTotjUdw","https://ap.wps.com/l/cbCaiaekWTotjUdw","pdf",10580527,16,"English","# Abstract\n## Background\n## Methods\n## Results\n# Introduction","[{\"question\":\"What is the main research focus of the study?\",\"answer\":\"The study examines how METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8, and clarifies the underlying METTL3-associated molecular axis.\"},{\"question\":\"How was METTL3-related correlation with prognosis evaluated?\",\"answer\":\"METTL3 and prognosis in thyroid cancer patients were assessed using immunohistochemistry.\"},{\"question\":\"What therapeutic sensitivity effects were observed when METTL3 expression changed?\",\"answer\":\"Silencing METTL3 promoted progression and dedifferentiation, while overexpressing METTL3 enhanced sensitivity of papillary and anaplastic thyroid cancer cells to chemotherapeutic drugs and iodine-131.\"}]","METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8 | PDF",1790042221,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc02aaea2b6b8c65249d8a02ffc86cba.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c944d939415badc9deb562346e7aa10a.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f807cbc1370abff1c884dcec73ff5d90.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51be04e8a672c6c2c1bd4783050ef90b.webp",980,1268]